As of 2026-04-02, the Intrinsic Value of Novartis AG (NOVN.SW) is 118.76 CHF. This NOVN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 122.90 CHF, the upside of Novartis AG is -3.40%.
The range of the Intrinsic Value is 85.19 - 198.14 CHF
Based on its market price of 122.90 CHF and our intrinsic valuation, Novartis AG (NOVN.SW) is overvalued by 3.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 85.19 - 198.14 | 118.76 | -3.4% |
| DCF (Growth 10y) | 102.89 - 224.68 | 139.37 | 13.4% |
| DCF (EBITDA 5y) | 66.84 - 81.47 | 71.65 | -41.7% |
| DCF (EBITDA 10y) | 85.48 - 107.59 | 93.77 | -23.7% |
| Fair Value | 132.23 - 132.23 | 132.23 | 7.59% |
| P/E | 95.74 - 137.72 | 111.16 | -9.6% |
| EV/EBITDA | 69.48 - 87.53 | 75.66 | -38.4% |
| EPV | 75.48 - 103.73 | 89.60 | -27.1% |
| DDM - Stable | 50.66 - 151.00 | 100.83 | -18.0% |
| DDM - Multi | 73.23 - 160.80 | 99.68 | -18.9% |
| Market Cap (mil) | 259,616.42 |
| Beta | 1.05 |
| Outstanding shares (mil) | 2,112.42 |
| Enterprise Value (mil) | 278,745.28 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.23% |
| Cost of Debt | 4.25% |
| WACC | 6.88% |